Eque-cel receives Orphan Drug status for myeloma treatment in South Korea
South Korea’s Ministry of Food and Drug Safety (MFDS) granted Orphan Drug Designation to equecabtagene autoleucel (Fucaso; eque-cel) for adults with relapsed or
Multiple Myeloma
Lymphoma
Aggressive B-Cell Lymphomas
News
FDA rejects glofitamab-GemOx sBLA in DLBCL
The US Food and Drug Administration (FDA) denied the supplemental Biologics License Application (sBLA) for glofitamab combined with gemcitabine and oxaliplatin (GemOx) for
Leukemia
Acute Myeloid Leukemia
News
Pathways & Perspectives with Alice Mims, MD
Meet Alice Mims, MD, a professor at The Ohio State University and senior medical director of the BeatAML study. Dr. Mims discusses venetoclax’s
18-IMCL
Meetings / Conferences
Income tied to survival outcomes in patients with DLBCL
A Finnish study found that patients with diffuse large B-cell lymphoma (DLBCL) who have low income levels have significantly worse survival outcomes.
Cellular Therapy
Multiple Myeloma
A third of myeloma patients in remission more than 5 years after cilta-cel treatment
Long-term follow-up from the CARTITUDE-1 study showed that 33% of heavily pretreated patients with multiple myeloma (MM) were in remission for 5 or
Ambassador Program
News
Society Updates
SOHO regional meeting in Brazil delivers again
SOHO President Phillip Scheinberg, MD, PhD, head of the Division of Hematology at the Hospital A Beneficência Portuguesa de São Paulo in Brazil, wrote
18-IMCL
Vitamin D supplementation does not improve DLBCL outcomes
A study found that low baseline vitamin D is associated with poor prognosis in patients with diffuse large B-cell lymphoma (DLBCL); however, supplementation
News
Society Updates
SOHO President Dr. Scheinberg drops hint on 2025 surprise
Phil Scheinberg, MD, PhD, chief of hematology at the Hospital A Beneficência Portuguesa de São Paulo in Brazil, shares his first impressions of
EHA 2025
Study supports frontline use of imetelstat for low-risk MDS patients ineligible for ESAs
A post-hoc analysis of pooled data from the IMerge trial found that patients with low-risk myelodysplastic syndromes (MDS) who were ineligible for erythropoiesis-stimulating
18-IMCL
News
ELARA trial: tisagenlecleucel response extends to 4 years in follicular lymphoma
Researchers presented 4-year follow-up data from the phase 2 ELARA study, showing that response to tisagenlecleucel continues to deepen in patients with follicular